GoodRx Holdings (GDRX) Research & Development (2019 - 2026)
GoodRx Holdings recorded quarterly Research & Development of $30.2 million in Q1 2026, up 4.28% quarter-over-quarter from $28.9 million in Q4 2025, and down 3.1% year-over-year from $31.1 million in Q1 2025.
GoodRx Holdings' Research & Development history runs 8 years deep, the most recent figure standing at $30.2 million for Q1 2026.
- In Q1 2026, Research & Development fell 3.1% year-over-year to $30.2 million; the TTM figure through Mar 2026 stood at $120.1 million (down 3.08% YoY), while the FY2025 annual figure was $121.0 million, down 2.2% from the prior year.
- Research & Development came in at $30.2 million for Q1 2026 at GoodRx Holdings, up from $28.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $39.6 million in Q3 2023 to a low of $28.9 million in Q4 2025.
- A 5-year average of $32.6 million and a median of $31.3 million in 2023 frame the typical range for Research & Development.
- Across the five-year window, Research & Development jumped 33.95% in 2022 and decreased 23.91% in 2024, its largest moves.
- GoodRx Holdings' Research & Development stood at $36.8 million in 2022, then declined by 12.89% to $32.0 million in 2023, then retreated by 0.91% to $31.7 million in 2024, then declined by 8.82% to $28.9 million in 2025, then rose by 4.28% to $30.2 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $30.2 million, $28.9 million, and $31.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 30.85 Bn | 24.28 Bn | 622.47 Mn | 198.79 Mn |
| 2 | BrightSpring Health Services | 12.29 Bn | 11.41 Bn | 482.22 Mn | - |
| 3 | Healthequity | 7.80 Bn | 7.48 Bn | 256.31 Mn | 67.77 Mn |
| 4 | Hinge Health | 4.82 Bn | 4.51 Bn | 154.23 Mn | 30.34 Mn |
| 5 | Doximity | 4.21 Bn | 3.46 Bn | 125.97 Mn | 39.11 Mn |
| 6 | Waystar Holding | 4.18 Bn | 4.03 Bn | 268.04 Mn | 18.37 Mn |
| 7 | 10x Genomics | 3.78 Bn | 3.24 Bn | 106.18 Mn | 56.85 Mn |
| 8 | Privia Health | 2.65 Bn | 2.28 Bn | 595.71 Mn | - |
| 9 | Omnicell | 1.95 Bn | 1.78 Bn | 140.36 Mn | 21.52 Mn |
| 10 | GoodRx Holdings | 1.05 Bn | 814.83 Mn | 112.95 Mn | 30.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.18 Mn |
| Dec 31, 2025 | 28.94 Mn |
| Sep 30, 2025 | 31.01 Mn |
| Jun 30, 2025 | 29.93 Mn |
| Mar 31, 2025 | 31.14 Mn |
| Dec 31, 2024 | 31.74 Mn |
| Sep 30, 2024 | 30.14 Mn |
| Jun 30, 2024 | 30.85 Mn |
| Mar 31, 2024 | 31.02 Mn |
| Dec 31, 2023 | 32.03 Mn |
| Sep 30, 2023 | 39.61 Mn |
| Jun 30, 2023 | 31.29 Mn |
| Mar 31, 2023 | 32.91 Mn |
| Dec 31, 2022 | 36.77 Mn |
| Sep 30, 2022 | 35.92 Mn |
| Jun 30, 2022 | 35.40 Mn |
| Mar 31, 2022 | 35.04 Mn |
| Dec 31, 2021 | 35.06 Mn |
| Sep 30, 2021 | 35.07 Mn |
| Jun 30, 2021 | 29.57 Mn |
| Mar 31, 2021 | 26.16 Mn |
| Dec 31, 2020 | 23.68 Mn |
| Sep 30, 2020 | 15.85 Mn |
| Jun 30, 2020 | 11.96 Mn |
| Mar 31, 2020 | 10.33 Mn |
| Dec 31, 2019 | 9.82 Mn |
| Sep 30, 2019 | 7.84 Mn |